

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM310366

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Larry Hopfenspirger		07/10/2014	INDIVIDUAL:
RECEIVING PARTY DATA			
Name:	Humanetics Corporation		
Street Address:	10400 Viking Drive, Suite 100		
City:	Eden Prairie		
State/Country:	MINNESOTA		
Postal Code:	55344		
Entity Type:	CORPORATION: MINNESOTA		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Registration Number:	2476865	WEIGHT LOSS ACCELERATOR	
Registration Number:	2724792	HUMANETICS THE SCIENCE OF SUPPLEMENTS	
Registration Number:	2942298	HUMANETICS THE SCIENCE OF SUPPLEMENTS.	
Registration Number:	2964802	7-KETO	
Registration Number:	2675783	7-KETO	
Serial Number:	78483769	AUGMUNE	
Serial Number:	77632866	AT-EASE	
CORRESPONDENCE DATA			
Fax Number:	6129778650		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	612-977-8229		
Email:	ababcock@briggs.com		
Correspondent Name:	Audrey Babcock		
Address Line 1:	80 South 8th Street		
Address Line 2:	2200 IDS Center		
Address Line 4:	Minneapolis, MINNESOTA 55402		
ATTORNEY DOCKET NUMBER:	42085.1		
NAME OF SUBMITTER:	Audrey J. Babcock		
SIGNATURE:	/Audrey J. Babcock/		

CH \$190.00 2476865

DATE SIGNED:	07/10/2014
---------------------	------------

Total Attachments: 5

source=release#page1.tif

source=release#page2.tif

source=release#page3.tif

source=release#page4.tif

source=release#page5.tif

RELEASE OF PATENT AND TRADEMARK SECURITY INTERESTS

This **RELEASE OF PATENT AND TRADEMARK SECURITY INTERESTS** ("**Release**"), is made and effective as of July 10, 2014 and granted by Larry Hopfenspirger (the "**Collateral Agent**"), as collateral agent for the secured parties under the Note Purchase Agreement referred to below (the "**Secured Parties**"), in favor of Humanetics Corporation, a Minnesota corporation, and its successors, legal representatives and assignees (collectively, the "**Grantor**").

WHEREAS, Grantor entered into a Convertible Note Purchase Agreement dated as of November 30, 2009 (the "**Note Purchase Agreement**"), with the Collateral Agent and the lender parties thereto;

WHEREAS, in connection with the Note Purchase Agreement, Grantor executed and delivered to the Collateral Agent (i) that certain Security Agreement dated as of November 30, 2009, made by and among the Grantor and the Collateral Agent (the "**Master Security Agreement**") and (ii) that certain Patent and Trademark Security Agreement, dated as of November 30, 2009 (the "**Patent Security Agreement**" and, together with the Master Security Agreement, the "**Security Agreements**");

WHEREAS, pursuant the Security Agreements, Grantor pledged and granted to the Collateral Agent for the ratable benefit of the Secured Parties a security interest in and to all of the right, title and interest of Grantor in, to and under the Intellectual Property Collateral (as defined below);

WHEREAS, the Patent Security Agreement was recorded at the United States Patent and Trademark Office at Reel 023594/Frame 0680 on December 4, 2009; and

WHEREAS, Grantor has requested that the Collateral Agent enter into this Release in order to accomplish and evidence the release and reassignment of any and all right, title and interest the Collateral Agent and the Secured Parties may have in the Intellectual Property Collateral pursuant to the Security Agreements.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Collateral Agent hereby states as follows:

1. Definition. The term "Intellectual Property Collateral", as used herein, shall mean all of Grantor's right, title and interest of every kind and nature as of the date hereof in the following (collectively, the "**Intellectual Property Collateral**");

a. all patents and patent applications, domestic or foreign, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses (including, without limitation, such patents and patent applications as described in Schedule A hereto), all rights to sue for past, present or future infringement thereof, all rights arising therefrom and pertaining thereto and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof;

b. all state (including common law), federal and foreign trademarks, service marks and trade names, URLs and domain names, and applications for registration of such trademarks, service marks and trade names, URLs and domain names, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses (including, without limitation, such marks, names and applications as described in Schedule B hereto), whether registered or unregistered and wherever registered, all rights to sue for past, present or future infringement or unconsented use thereof, all rights arising therefrom and pertaining thereto and all reissues, extensions and renewals thereof;

c. the entire goodwill of or associated with the businesses now or hereafter conducted by the Company connected with and symbolized by any of the aforementioned properties and assets;

d. all general intangibles (as defined in the UCC) and all intangible intellectual or other similar property of the Company of any kind or nature, associated with or arising out of any of the aforementioned properties and assets and not otherwise described above; and

e. all products and proceeds of any and all of the foregoing.

2. Release of Security Interest. Collateral Agent, on behalf of itself and the Secured Parties, their successors, legal representatives and assigns, terminates, releases and discharges its security interest in and to the Intellectual Property Collateral, and all other right, title, and interest in and to the Intellectual Property Collateral and reassigns to the Grantor any and all such right, title and interest that it may have in the Intellectual Property Collateral.


3. Further Assurances. Collateral Agent agrees to execute, acknowledge, procure and deliver to Grantor any and all further documents or instruments and do any and all further acts which Grantor (or their respective agents, designees or assignees) reasonably request in order to confirm, effectuate or record this Release and Grantor's (or their assignees') right, title and interest in and to the Intellectual Property Collateral.

4. Governing Law. This Release and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Release and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of Minnesota, without giving effect to any choice or conflict of law provision or rule (whether of the State of Minnesota or any other jurisdiction).

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, Collateral Agent has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

COLLATERAL AGENT:


Larry Hopfenspirger

SCHEDULE A
to
PATENT AND TRADEMARK SECURITY AGREEMENT

Issued U.S. Patents of the Company

REF	PATENT #	ISSUE DATE	TITLE
1.	5,292,730	March 8, 1994	Modulation of immune system with 5-Androstenes
2.	5,296,481	March 22, 1994	Treatment process for promoting weight loss employing a substituted 5-Androstene
3.	5,424,463	June 13, 1995	5-Androstenes Useful for Promoting Weight Maintenance or Weight Loss
4.	5,585,371	December 17, 1996	Treatment of immune system with 5-Androstene
5.	6,153,606	November 28, 2000	Improving Memory by the Administration of 5-Androstene-3-Beta-ol-7, 17-Dione and 3 Beta Esters Thereof
6.	6,465,446	October 15, 2002	Treatment of dermatitis by the topical application of 5-Androstene-3 β -ol-7, 17 Dione and metabolizable precursors thereof
7.	6,489,313	December 3, 2002	Memory by the administration of 5-Androstene-3 β -ol-7, 17 Dione and 3 β Esters thereof
8.	6,518,318	February 11, 2003	Stimulating transport of Glucose into Animal Tissue by Administration of Pinitol
9.	7,199,116	April 3, 2007	Method of Modulating the Basal Metabolic Rate of a Dieting Mammal by Administration of a Metabolic Modulating Agent to the Dieting Mammal
10.	7,553,829	June 30, 2009	Treatment of Chronic Fatigue Syndrome and Fibromyalgia Syndrome

Pending U.S. Patent Application of the Company

None.

Issued International Patents of the Company

None.

Pending International Patent Applications of the Company

REF	COUNTRY	SERIAL NO.	TITLE
1.	Japan	2004-4160	Method of Modulating the Basal Metabolic Rate of a Dieting Mammal by Administration of a Metabolic Modulating Agent to the dieting Mammal (7-oxo DHEA)

SCHEDULE B
to
PATENT AND TRADEMARK SECURITY AGREEMENT

Trademarks of the Company Registered with USPTO

REF	MARK	REG NUMBER	REG DATE
1.	WEIGHT LOSS ACCELERATOR	2,476,865	8/7/2001
2.	HUMANETICS THE SCIENCE OF SUPPLEMENTS (and design)	2,724,792	6/10/2003
3.	HUMANETICS THE SCIENCE OF SUPPLEMENTS (and design)	2,942,298	4/19/2005
4.	7-KETO	2,964,802	7/5/2005
5.	7-KETO (and design)	2,675,783	1/21/2003

Trademark Applications of the Company Pending at USPTO

REF	MARK	SERIAL NUMBER	FILING DATE
1.	AUGMUNE (Abandoned)	78/483,769	09/15/2004
2.	AT-EASE	77/632866	12/15/2008

International Registered Trademarks of the Company

REF	COUNTRY	MARK	REG NUMBER	REG DATE
1.	Canada	7-KETO (and design)	606,108	03/24/2004
2.	Canada	7-KETO	594,851	11/17/2003

International Pending Trademark Applications of the Company

REF	COUNTRY	MARK	REG NUMBER	REG DATE
1.	Israel	AT-EASE	217457	12/17/2008